<DOC>
	<DOCNO>NCT00486005</DOCNO>
	<brief_summary>Evaluate efficacy nizatidine reducing/limiting weight gain patient schizophrenia treatment olanzapine least two month evaluate treatment effect Eating Inventory , BPRS , number treatment , emergent adverse event , change vital sign , laboratory result extrapyramidal effect .</brief_summary>
	<brief_title>Weight Gain Management Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Nizatidine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients , men woman , age 18 65 year Patients must schizophrenia meet disease diagnostic criterion define DSMIV Sections 295.10 , 295.20 , 295.30 , 295.90 clinically acute phase , accordance judgment investigator Patients use 5 mg/day 20 mg/day olanzapine period le 2 month great 6 month increase least 5 % corporal weight since begin treatment olanzapine . The individual must trustworthy , level understanding enough carry test examination demand protocol , understand nature study sign informed consent Women potential become pregnant must use medically acceptable reliable mean birth control . Participation clinical study another drug investigation within period 1 month ( 30 day ) entrance study ( Visit 1 ) People use clozapine within period 12 month begin study People diagnosis diabetes mellitus type I II without adjusted clinical control initiate medication use glycemic control last 6 month DSMIV substance ( except nicotine caffeine ) dependence within past 30 day Current participation program weight loss</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>